FR2870743A1 - Preventing and/or treating obesity, excessive weight and associated disorders, e.g. cellulite, by medicinal, veterinary, cosmetic or nutraceutical use of natural or synthetic alkylfurans - Google Patents

Preventing and/or treating obesity, excessive weight and associated disorders, e.g. cellulite, by medicinal, veterinary, cosmetic or nutraceutical use of natural or synthetic alkylfurans

Info

Publication number
FR2870743A1
FR2870743A1 FR0502758A FR0502758A FR2870743A1 FR 2870743 A1 FR2870743 A1 FR 2870743A1 FR 0502758 A FR0502758 A FR 0502758A FR 0502758 A FR0502758 A FR 0502758A FR 2870743 A1 FR2870743 A1 FR 2870743A1
Authority
FR
France
Prior art keywords
cosmetic
synthetic
natural
preventing
veterinary
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0502758A
Other languages
French (fr)
Other versions
FR2870743B1 (en
Inventor
Philippe Msika
Antoine Piccirilli
Nathalie Piccardi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Expanscience SA
Original Assignee
Laboratoires Expanscience SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0502758A priority Critical patent/FR2870743B1/en
Application filed by Laboratoires Expanscience SA filed Critical Laboratoires Expanscience SA
Priority to JP2007514019A priority patent/JP4842260B2/en
Priority to ES05773033T priority patent/ES2340510T3/en
Priority to DE602005020274T priority patent/DE602005020274D1/en
Priority to PL05773033T priority patent/PL1750695T3/en
Priority to US11/597,634 priority patent/US7589121B2/en
Priority to CA2567479A priority patent/CA2567479C/en
Priority to CN2005800173724A priority patent/CN1960723B/en
Priority to AT05773033T priority patent/ATE462431T1/en
Priority to EP05773033A priority patent/EP1750695B1/en
Priority to MXPA06013885A priority patent/MXPA06013885A/en
Priority to PCT/FR2005/001312 priority patent/WO2005117857A1/en
Publication of FR2870743A1 publication Critical patent/FR2870743A1/en
Priority to HK07108349.4A priority patent/HK1100279A1/en
Priority to JP2011135366A priority patent/JP5405528B2/en
Application granted granted Critical
Publication of FR2870743B1 publication Critical patent/FR2870743B1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Organic Chemistry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Birds (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Cosmetics (AREA)

Abstract

Use of natural or synthetic alkylfuran(s) (I) is claimed in the production of medicaments or veterinary compositions for preventing and/or treating obesity. An independent claim is also included for use of cosmetic or nutraceutical compositions containing (I) for the cosmetic treatment of disorders associated with excessive weight. ACTIVITY : Anorectic; Antidiabetic; Antilipemic; Cardiant; Neuroprotective; Dermatological; Nephrotropic; Ophthalmological. In tests in rats fed a high fat/high sugar diet, administration of avocado non-saponifiables (containing 98 wt. % 2-(heptadeca-8(Z),11(Z)-dienyl)-furan) at 0.25% of the diet for 3 weeks reduced the average body weight to 82.7% of the control value. MECHANISM OF ACTION : None given in the source material.
FR0502758A 2004-05-28 2005-03-21 USE OF ALKYL FURANS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE WEST OVERLOAD Active FR2870743B1 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR0502758A FR2870743B1 (en) 2005-03-21 2005-03-21 USE OF ALKYL FURANS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE WEST OVERLOAD
MXPA06013885A MXPA06013885A (en) 2004-05-28 2005-05-27 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight.
DE602005020274T DE602005020274D1 (en) 2004-05-28 2005-05-27 USE OF FURANAL CYLINDERS FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF ADIPOSITAS AND COSMETIC TREATMENT OF OVERWEIGHT
PL05773033T PL1750695T3 (en) 2004-05-28 2005-05-27 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
US11/597,634 US7589121B2 (en) 2004-05-28 2005-05-27 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
CA2567479A CA2567479C (en) 2004-05-28 2005-05-27 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
CN2005800173724A CN1960723B (en) 2004-05-28 2005-05-27 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
AT05773033T ATE462431T1 (en) 2004-05-28 2005-05-27 USE OF FURANALKYLENE FOR THE PRODUCTION OF A MEDICINAL PRODUCT FOR THE TREATMENT OF OBESITY AND COSMETIC TREATMENT OF OBESITY
JP2007514019A JP4842260B2 (en) 2004-05-28 2005-05-27 Use of furan alkyls to produce drugs for the treatment of obesity and cosmetic treatment of overweight
ES05773033T ES2340510T3 (en) 2004-05-28 2005-05-27 USE OF RENTAL-FURANS FOR THE PREPARATION OF A MEDICINAL PRODUCT INTENDED FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE EXCEESS OF WEIGHT.
PCT/FR2005/001312 WO2005117857A1 (en) 2004-05-28 2005-05-27 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
EP05773033A EP1750695B1 (en) 2004-05-28 2005-05-27 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
HK07108349.4A HK1100279A1 (en) 2004-05-28 2007-07-31 Use of furan alkyls for preparing a drug for treating obesity and cosmetically treating overweight
JP2011135366A JP5405528B2 (en) 2004-05-28 2011-06-17 Use of furan alkyls to produce drugs for the treatment of obesity and cosmetic treatment of overweight

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0502758A FR2870743B1 (en) 2005-03-21 2005-03-21 USE OF ALKYL FURANS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE WEST OVERLOAD

Publications (2)

Publication Number Publication Date
FR2870743A1 true FR2870743A1 (en) 2005-12-02
FR2870743B1 FR2870743B1 (en) 2012-03-09

Family

ID=34978800

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0502758A Active FR2870743B1 (en) 2004-05-28 2005-03-21 USE OF ALKYL FURANS FOR THE PREPARATION OF A MEDICAMENT FOR THE TREATMENT OF OBESITY AND FOR THE COSMETIC TREATMENT OF THE WEST OVERLOAD

Country Status (1)

Country Link
FR (1) FR2870743B1 (en)

Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775480A1 (en) * 1993-10-25 1997-05-28 S. Richard Huber Novel lipidic furans useful for skin therapeutics
WO2001021605A2 (en) * 1999-09-22 2001-03-29 Laboratoires Pharmascience Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food
EP1110548A1 (en) * 1998-09-01 2001-06-27 Janiftec, Inc. Substances having antiobese and visceral fat-reducing functions and utilization thereof
WO2002058698A2 (en) * 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
WO2004002435A2 (en) * 2002-06-27 2004-01-08 Laboratoires Expanscience Use of isoflavones for promoting slimming
WO2004112741A1 (en) * 2003-06-18 2004-12-29 Laboratoires Expanscience Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0775480A1 (en) * 1993-10-25 1997-05-28 S. Richard Huber Novel lipidic furans useful for skin therapeutics
EP1110548A1 (en) * 1998-09-01 2001-06-27 Janiftec, Inc. Substances having antiobese and visceral fat-reducing functions and utilization thereof
WO2001021605A2 (en) * 1999-09-22 2001-03-29 Laboratoires Pharmascience Method for extracting compounds of furan lipids and polyhydroxylated fatty alcohols of avocado, composition based on said compounds and use of said compounds in therapy, cosmetics and food
WO2002058698A2 (en) * 2001-01-26 2002-08-01 Chugai Seiyaku Kabushiki Kaisha Malonyl-coa decarboxylase inhibitors useful as metabolic modulators
US20030120073A1 (en) * 2001-04-25 2003-06-26 Seto Christopher T. Alpha-ketocarboxylic acid based inhibitors of phosphoryl tyrosine phosphatases
WO2003007888A2 (en) * 2001-07-20 2003-01-30 Adipogenix, Inc. Fat accumulation-modulating compounds
WO2004002435A2 (en) * 2002-06-27 2004-01-08 Laboratoires Expanscience Use of isoflavones for promoting slimming
WO2004112741A1 (en) * 2003-06-18 2004-12-29 Laboratoires Expanscience Cosmetic use of a composition containing at least one oxazoline, serving as an active substance, as a slimming product and/or for preventing and/or treating cellulite

Also Published As

Publication number Publication date
FR2870743B1 (en) 2012-03-09

Similar Documents

Publication Publication Date Title
ES2239010T3 (en) CHRYSANTHEMUM MATRICAIRE EXTRACTS (TANACETUM PARTHENIUM) USED AGAINST INFLAMMATORY DISORDERS.
BR0109336A (en) A medicament for the prevention, amelioration and / or treatment of a diabetic complication, a suitable or usable medicinal drug thereof, a method for preventing, ameliorating and / or treating a diabetic complication, and neuropathy, and uses of a sugar reducing agent. in postprandial blood and at least one agent selected from an antihypertensive agent, a vasodilating agent and an antihyperlipidemic agent
JPH0564129B2 (en)
MY140576A (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
UY26425A1 (en) FORMULATION AND ANTI-DIABETIC METHOD
UA92498C2 (en) Cannabinoid active pharmaceutical ingredient for improved dosage forms
BRPI0811347A2 (en) "medicinal herbaceous extract with anti-obesity effect"
WO2007081486A3 (en) Oral administration of defensins to treat intestinal diseases
MX2023014327A (en) 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and medical uses thereof.
CN104146908A (en) Body building and weight reducing peony composite essential oil and preparation method thereof
EP3954367A1 (en) Dietary supplement for the prevention and/or treatment of pain and/or neuropathies
BR0115390A (en) Formulations for controlled release of metformin, controlled release of oral dosage form, method of lowering blood glucose levels, use of dosage form
FR2870743A1 (en) Preventing and/or treating obesity, excessive weight and associated disorders, e.g. cellulite, by medicinal, veterinary, cosmetic or nutraceutical use of natural or synthetic alkylfurans
CN101926857B (en) Traditional Chinese medicinal liniment for treating vitiligo
EP3508201A3 (en) Glycine as a diet supplement for use in the treatment skin problems that result from underlying collagen disorders and and cosmetic uses thereof
CN1237445A (en) Ginkgo American ginseng calcium capsule
JP4355967B2 (en) Pharmaceutical composition
CN112007039B (en) A pharmaceutical composition containing fluoxetine and vitamin D3Or derivatives thereof, and uses thereof
DE502005001398D1 (en) Skin care product containing ursolic acid and ginkgo extract
JP5730548B2 (en) CGRP response promoter
KR101103157B1 (en) Therapeutic agent for diabetic neuropathy
JP6026706B2 (en) Skin symptom improving agent, hair restorer or slimming agent
JP2003523920A5 (en)
JP2018058828A (en) Leucine derivatives, compositions comprising the same, and applications thereof
US10434087B1 (en) Dietary supplement formulations

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19

PLFP Fee payment

Year of fee payment: 20